Cost of medical care for HIV-infected patients within a regional population from 1997 to 2006

HIV Medicine

Volumn 9, Issue 9, 2008, Pages 721-730

  Krentz, Hartmut B ^a,b   Gill, M J ^a,b  

^a Southern Alberta Clinic   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

Author keywords

AIDS; Cost of care; Health economics; Healthcare costs; HIV

Indexed keywords

AMPRENAVIR; AMPRENAVIR PHOSPHATE; ANTIINFECTIVE AGENT; ANTIRETROVIRUS AGENT; ATAZANAVIR; ENFUVIRTIDE; LOPINAVIR PLUS RITONAVIR; TENOFOVIR; TUBERCULOSTATIC AGENT;

ADOLESCENT; ADULT; ARTICLE; CANADA; CD4 LYMPHOCYTE COUNT; COHORT ANALYSIS; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EXPOSURE; EARLY DIAGNOSIS; FEMALE; HEALTH CARE COST; HEALTH CARE UTILIZATION; HEALTH ECONOMICS; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MAJOR CLINICAL STUDY; MALE; MYCOBACTERIOSIS; MYCOBACTERIUM INTRACELLULARE AVIUM; OUTPATIENT CARE; PATIENT CARE; PNEUMOCYSTIS PNEUMONIA; PRIORITY JOURNAL; RETROSPECTIVE STUDY; RISK REDUCTION;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ALBERTA; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CD4 LYMPHOCYTE COUNT; COST-BENEFIT ANALYSIS; FEMALE; HEALTH CARE COSTS; HIV INFECTIONS; HIV-1; HOSPITALIZATION; HUMANS; MALE; MIDDLE AGED; PRACTICE GUIDELINES AS TOPIC; RETROSPECTIVE STUDIES;

EID: 54049116313     PISSN: 14642662     EISSN: 14681293     Source Type: Journal    
DOI: 10.1111/j.1468-1293.2008.00613.x     Document Type: Article

References (35)

1. Levy A, James D, Johnston KM et al. The direct cost of HIV/AIDS care. Lancet Infec Dis 2006; 6: 171-177.
2. Krentz HB, Auld C, Gill MJ. The changing direct costs of medical care for patients with HIV/AIDS, 1995-2001. CMAJ 2003; 169: 106-110.
3. Krentz HB, Gill MJ. Impact of practice changes on an antiretroviral budget in an HIV care program. Dis Manage Health Outcomes 2005; 13: 209-217.
4. Bernal JA, Romero SP, Garcia-Gil D et al. Costs of HIV management: 1995 to 2003. 15th International AIDS Conference. Bangkok, Thailand, July 2003 [Abstract TuPeD5159].
5. Bogaards JA, Dijkgraaf MGW, Prins JM et al. Changing direct costs of HIV treatment since the introduction of HAART in the Netherlands. 15th International AIDS Conference. Bangkok, Thailand, July 2003 [Abstract TuPeE5388].
6. Decock RA, Deporter AM, De Graeve D et al. Direct costs of health care for HIV/AIDS patients in Belgium. AIDS Care 2001; 13: 721-731.
7. Gebo KA, Chaisson RE, Folkemer JG et al. Cost of HIV medical care in the era of highly active antiretroviral therapy. AIDS 1999; 13: 963-969.
8. Kimura H. Cost of HIV treatment in highly active antiretroviral therapy in Japan. Nippon Rinsho 2002; 60: 813-816.
9. Miners HH, Sabin CA, Truemen P et al. Assessing the cost-effectiveness of HAART for adults with HIV in England. HIV Med 2001; 2: 52.
10. Stoll M, Claes C, Schulte E et al. Direct costs for the treatment of HIV-infection in a German cohort after the introduction of HAART. Eur J Med Res 2002; 7: 463-471.
11. Youle M, Trueman P, Simpson K. Health economics in HIV disease. A review of the European literature. Pharmacoeconomics 1999; 15 (Suppl. 1): 1-12.
12. Beck EJ, Mandalia S, Gaudreault M et al. The cost-effectiveness of highly active antiretroviral therapy, Canada 1991-2001. AIDS 2004; 18: 2411-2418.
13. Walensky RP, Paltiel AD, Losina E et al. The survival benefits of AIDS treatment in the United States. JID 2006; 194: 11-19.
14. Freedberg KA, Losina E, Weinstein MC et al. The cost effectiveness of combined antiretroviral therapy for HIV disease. N Engl J Med 2001; 344: 824-831.
15. Beck EJ, Miners AH, Tolley K. The cost of HIV treatment and care. A global review. Pharmacoeconomics 2001; 19: 13-39.
16. Bozzette SA, Joyce G, McCaffery DF et al. Expenditures for the care of HIV-infected patients in the era of highly active antiretroviral therapy. N Engl J Med 2001; 344: 817-831.
17. Branson BM, Handsfield HH, Lampe MA et al. Revised recommendations for HIV testing of adults, adolescents, and pregnant women in health-care settings. MMWR Recomm Rep 2006; 55: 1-17.
18. Walensky RP, Weinstein MC, Kimmel AD et al. Routine human immunodeficiency virus testing: An economic evaluation of current guidelines. Am J Med 2005; 118: 292-300.
19. The Strategies for Management of Antiretroviral Therapy (SMART) Study Group. CD4 count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355: 2283-2296.
20. Gill MJ, Krentz HB. Costing implications of recent treatment interruption studies. AIDS 2006; 20: 2239-2240.
21. Chen RY, Accortt NA, Westfall AO et al. Distribution of health care expenditures for HIV-infected patients. CID 2006; 42: 1003-1010.
22. Krentz HB, Ault C, Gill MJ. The high cost of medical care for patients who present late with HIV infection. HIV Med 2004; 5: 93-98.
23. Mauskopf J, Kitahata M, Kauf T et al. HIV antiretroviral treatment. Early versus later. J Acquir Immune Defic Syndr 2005; 39: 562-569.
24. Jones R, Gazzard B. The cost of antiretroviral drugs and influence on prescribing polices. Int J STD AIDS 2006; 17: 499-506.
25. Sax PE, Islam R, Walensky RP et al. Should resistance testing be performed for treatment-naïve HIV-infected patients? A cost-effectiveness analysis. Clin Infect Dis 2005; 41: 1316-1323.
26. Gebo KA, Moore RD. Treatment of HIV infection in the older patient. Expert Rev Antiinfect Ther 2004; 2: 733-743.
27. Inungu JN, Mokotoff ED, Kent JB. Characteristics of HIV infection in patients fifty years or older in Michigan. AIDS Patient Care STDS 2001; 15: 567-573.
28. Knodel J, Van Landingham M. The impact of the AIDS epidemic on older persons. AIDS 2002; 16 (Suppl. 3): 77-83.
29. Tumbarello M, Rabagliati R, De Gaetano Donati K et al. Older HIV-positive patients in the era of highly active antiretroviral therapy: Changing of a scenario. AIDS 2003; 17: 128-131.
30. Fleishman JA, Gebo KA, Reilly ED et al. Hospital and outpatient health services utilization among HIV-infected adults in care 2000-2002. Med Care 2005; 43 (Suppl. 9): 40-52.
31. Krentz HB, Dean S, Gill MJ. Longitudinal assessment (1995-2003) of hospitalizations of HIV-infected patients within a geographical population in Canada. HIV Med 2006; 7: 457-466.
32. Schlichemeyer R, Chamber C, Gill MJ. The oncology impact of highly active antiretroviral therapy (HAART). J Oncol Pharm Practice 2007; 13: 17-25.
33. Krentz HB, Gill MJ. Clinical, demographic, and health resource utilization characteristics of HIV-infected sub-Saharan immigrants and refugees followed at the Southern Alberta Clinic. J Infect Dis Med Microbiol 2006; 16 (Suppl. A) [Abstract 255P].
34. Giordano TP, Gifford AL, White AC et al. Retention in care: A challenge to survival with HIV infection. Clin Infect Dis 2007; 44: 1493-1499.
35. Gingues S, Gill MJ. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in southern Alberta. HIV Med 2006; 7: 369-377.